Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,264 people get EW articles and Market Currents by email alert.
Get email alerts on EW »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
Edwards Lifesciences And The TransCatheter Aortic Valves MarketAmod Saul • Mon, Oct 22, 2012 -
-
-
-
Edwards Lifesciences: Earnings PreviewZacks Investment Research • Tue, Apr 24, 2012 -
-
Edwards Lifesciences: Earnings PreviewZacks Investment Research • Mon, Oct 17, 2011
-
Edwards Lifesciences' Market Value Implies Strong Underlying GrowthJeremy Johnson • Mon, Sep 26, 2011 -
Edwards Lifesciences Corp.'s New Share Buyback ProgramZacks Investment Research • Mon, Sep 19, 2011
-
Edwards Lifesciences: Earnings PreviewZacks Investment Research • Wed, Jul 20, 2011
-
Edwards Lifesciences: Earnings PreviewZacks Investment Research • Wed, Apr 20, 2011
-
Edwards Lifesciences Beats 3Q Estimates and Raises OutlookZacks Investment Research • Tue, Oct 26, 2010
-
-
Edwards Lifesciences Receives FDA WarningSA Editor Eli Hoffmann • Wed, Feb 21, 2007
-
-
-
-
-
-
-
-
-
-
-
-
-
Calendar Spreads Continue To Work Very Well And Pay OffJohn Naccarelli • Wed, Oct 31, 2012 -
-
Medicating Your Portfolio With Medical Device Companies: Part 2JoeNatural • Tue, Oct 16, 2012 -
-
-
-
4 Growth Stocks With Positive Momentum And Low DebtArie Goren • Fri, Oct 5, 2012 -
-
Edwards Lifesciences Corp. Q4 2009 Earnings Call TranscriptFri, Feb 5, 2010
-
Edwards Lifesciences Corporation Q3 2009 Earnings Call TranscriptWed, Oct 21, 2009
-
Edwards Lifesciences Corporation Q1 2009 Earnings Call TranscriptTue, Apr 28, 2009
-
Edwards Lifesciences Corporation. Q4 2008 Earnings Call TranscriptTue, Feb 3, 2009
-
Edwards Lifesciences Corp. Q3 2008 Earnings Conference Call TranscriptTue, Oct 21, 2008
-
Edwards Lifesciences Corp. Q2 2008 Earnings Call TranscriptTue, Jul 22, 2008
-
Edwards Lifesciences Corp. Q1 2008 Earnings CallWed, Apr 23, 2008
-
Edwards Li Fesciences Corp. Q4 2007 Earnings Call TranscriptWed, Feb 6, 2008
-
at MarketWatch.com (Thu, 4:23PM)
-
Marketwire (Jun 4, 2013)
-
at MarketWatch.com (May 31, 2013)
-
Marketwire (May 29, 2013)
-
Marketwire (May 21, 2013)
-
at MarketWatch.com (May 14, 2013)
-
at CNBC.com (May 14, 2013)
-
Marketwire (May 14, 2013)
-
Marketwire (May 14, 2013)
-
Marketwire (May 8, 2013)
-
Marketwire (May 7, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at MarketWatch.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 23, 2013)
-
Marketwire (Apr 23, 2013)
-
Marketwire (Apr 17, 2013)
EW vs. ETF Alternatives
Company Description
Edwards Lifesciences Corporation is a global leader in products and technologies designed to treat advanced cardiovascular disease. The Company is focused specifically on technologies that treat structural heart disease and critically ill patients.
Cardiovascular disease is the number-one... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 29, 4:44 PM Edwards Lifesciences (EW) says it's received a warning letter from the FDA resulting from an inspection of its facility in Draper, Utah, which was concluded in February. The letter relates specifically to EW's execution of quality systems within its Cardiac Surgery Systems business, and addresses its design and process validation, corrective and preventive actions, finished device acceptance and packaging. The company doesn't expect any material impact on its 2013 financial guidance from the letter. 1 Comment [Healthcare]
- Tuesday, May 14, 9:33 AM Edwards Lifesciences (EW +2.7%) news roundup: Company authorizes a new $750M buyback program and says it will complete the remainder ($140M) of its previously authorized repurchase program during Q2; CEO Michael Mussallem will purchase $5M worth of shares tomorrow at either Wednesday's closing price or the average closing price for the 10 trading days ending Monday, whichever is higher; CFO Thomas Abate will retire this year. Despite a 5-day, ~5% rally, the shares are still reeling from April 24th's post-earnings dive and subsequent downgrades. Comment! [Healthcare, On the Move]
-
Wednesday, April 24, 12:44 PM
Midday top 10 gainers: RSOL +31%. NOR +27%. BKI +26%. BYD +18%. IRBT +15%. CHCI +14%. RVLT +13%. FXEN +12%. TRQ +12%. LL +12%.
Midday top 10 losers: VOCS -37%. VLTC -24%. EW -23%. UIS -23%. DV -21%. CCCL -15%. MCOX -14%. MEG -14%. SCON -13%. MACK -13%. Comment! [On the Move] -
Wednesday, April 24, 9:11 AM
Premarket gainers: BKI +26%. PBTH +11%. LL +7%. PSTI +5%.
Losers: VOCS -31%. UIS -20%. EW -19%. RES -13%. AWAY -9%. SCON -9%. JNPR -7%. SVU -7%. PNRA -6%. CREE -6%. Comment! [On the Move] - Wednesday, April 24, 8:14 AM The cuts come fast following Edward Lifesciences' (EW) earnings miss last night: "We no longer have confidence in management executing on the (Sapien) U.S. launch," says RBC, cutting its PT to $72 from $102. "We would not be buyers (at $70)," says Lazard. JPM: "We've cut our price target to $68, but the risks in our view still point to the downside ... growth is likely to decelerate further in 2014 and even more so in 2015." Read what all of these analysts had to say on the earnings call. Shares -17% premarket. Comment! [Healthcare, On the Move]
- Tuesday, April 23, 4:11 PM Edwards Lifesciences (EW): Q1 EPS of $0.72 misses by $0.04. Revenue of $496.7M (+8.2% Y/Y) misses by $21.99M. Shares -10.6% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Tuesday, April 23, 12:10 AM Notable earnings after Tuesday’s close: AAPL, ACC, AMGN, AWAY, BCR, BRCM, CREE, DV, EW, FBC, FTI, HA, HBI, HLIT, HTS, IRBT, ITC, JNPR, LIFE, NBR, NFX, NSC, OI, OII, OMI, PACB, PLCM, PNRA, RFMD, RHI, T, UIS, USNA, VMW, WRB, YUM, ZIXI Comment! [Earnings]
- Monday, April 22, 5:35 PM Notable earnings after Tuesday’s close: AAPL, ACC, AMGN, AWAY, BCR, BRCM, CREE, DV, EW, FBC, FTI, HA, HBI, HLIT, HTS, IRBT, ITC, JNPR, LIFE, NBR, NFX, NSC, OI, OII, OMI, PACB, PLCM, PNRA, RFMD, RHI, T, UIS, USNA, VMW, WRB, YUM, ZIXI Comment! [Earnings]
- Tuesday, February 5, 2:56 PM Jefferies analyst Raj Denhoy comes out defending Edwards Lifesciences (EW -6.5%) on weakness today, reiterating his Buy rating and upping his price target to $114 from $100. Denhoy says its quarter was solid, and the higher price target is due to strong US Sapien transcatheter heart valve sales, which are tracking ahead of expectations. Comment! [Healthcare, Earnings, On the Move]
- Monday, February 4, 5:49 PM More on Edwards Lifesciences (EW): Q4 beats on both EPS and revenue as total sales jump 18% Y/Y. Net profit also soared by 44% versus the prior year period as revenue improved across the medical-device company's segments - led by sales of transcatheter heart valves - and the period was also boosted by a tax benefit. Looking forward, the company expects to benefit from October's FDA decision to expand the approved use of its Sapien device to include high-risk surgery patients, and the company is investing heavily into that expansion. Shares +0.5% AH. Comment! [Healthcare, Earnings]
- Monday, February 4, 4:06 PM Edwards Lifesciences (EW): Q4 EPS of $0.9 beats by $0.13. Revenue of $510.5M (+18.7% Y/Y) beats by $11.04M. Shares +1% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Monday, February 4, 12:10 AM Notable earnings after Monday’s close: ACLS, APC, APKT, ARRY, BIDU, EW, GGP, GILD, HI, HIG, HOLX, LEG, LIFE, MDU, MKL, SIMO, SWI, YUM Comment! [Earnings]
- Sunday, February 3, 5:35 PM Notable earnings after Monday’s close: ACLS, APC, APKT, ARRY, BIDU, EW, GGP, GILD, HI, HIG, HOLX, LEG, LIFE, MDU, MKL, SIMO, SWI, YUM Comment! [Earnings]
- Monday, November 19, 2012, 3:56 PM As the appetite for waging war against Obamacare wanes, smaller fixes are starting to come into the limelight, and are becoming increasingly more realistic, as long as every minor issue doesn’t blow up into a full-scale battle. One small fight is now being picked by medical device companies, who are trying to use the debate to get ObamaCare's tax on medical devices repealed, and it appears that some Democrats may support that initiative. Comment! [Healthcare]
- Monday, November 19, 2012, 2:23 PM St. Jude Medical (STJ +2%) says its received European approval for its Portico heart valve replacement device. The approval gives STJ access to a burgeoning market for the devices, and the news gives a much-needed lift to the stock after a string of negative headlines in recent months has driven the stock down near 52-week lows. Since October alone, STJ has shaved nearly 17% off its market cap. Comment! [Healthcare, On the Move]
- Tuesday, November 13, 2012, 3:18 PM Edwards Lifesciences(EW +1.7%) says a U.S. Appeals Court has affirmed a 2010 federal jury decision that Medtronic (MDT +0.3%) is infringing the company's U.S. Andersen transcatheter heart valve patent, as well as an initial payment award to EW of $74M. The court also ordered the trial court to reconsider EW's request for a permanent injunction that would prohibit the sale of Medtronic's CoreValve system in the U.S. Comment! [Healthcare]
-
Black Coral Research
$EW hit a new 52-week low today and is down almost 25% since our article before earnings http://seekingalpha.com/a/t5pr - View all 0 replies
-
Alan Brochstein
$EW pounded on miss and lower guidance - not bad at 70, could be a buy at 68 (but I prefer $STJ) - View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
Capitalist Bull
Short Ideas http://stks.co/eR1t produced big gains since negative LSA in Feb. http://stks.co/eR1u $AAPL $BIDU $SLV $GLD $GDX $CRUS $EW $GDX - View all 0 replies
-
- View all 0 replies
-
- View all 8 replies
-
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 8 replies
-
-
-
- View all 1 replies
-
-
- View all 1 replies
-
